map
United States United States
close
Canada Canada
close
Thunder Bay, ON, Canada
United States United States
close
Uganda Uganda
close
Brazil Brazil
close
Sao Paulo, Brazil
Germany Germany
close
Hamburg, Germany
United States United States
close
Jupiter, FL

The HOPE Collaboratory is made up of a diverse, multidisciplinary and international group of HIV researchers dedicated to developing a cure for HIV.

COL Julie Ake
Director, U.S. Military HIV Research Program, Walter Reed Army Institute of Research
Bethesda, MD

COL Ake will facilitate collaboration with MHRP, including their research team and their clinical cohort studies in the US and Africa.

Walter Reed Army Institute of Research

Vivian Avelino-Silva, MD, PhD
University of Sao Paulo School of Medicine
Sao Paulo, Brazil

Dr. Avelino-Silva works as a co-investigator for the study in Sao Paulo, Brazil, participating in the enrollment and follow-up of transgender and chronic liver disease participants.

University of Sao Paulo School of Medicine

Jan Chemnitz, PhD
Heinrich Pette Institute – Leibniz Institute for Experimental Virology
Hamburg, Germany

Dr. Chemnitz is working to find a cure to HIV using next generation genome editing methods.

Heinrich Pette Institute – Leibniz Institute for Experimental Virology

Patricia Defechereux, PhD
Gladstone Institutes
San Francisco, CA

Dr. Patricia Defechereux lead's the HOPE Community activities as the HOPE Community Engagement Coordinator.

Cedric Feschotte, PhD
Researcher
Cornell University
Ithica, NY

Our group will learn how T cells naturally silence endogenous retroviruses, which are ancient and permanent residents of our genome, to design new HIV repressors.

Cornell University

Sara Gianella
University of California – San Diego
San Diego, CA

Dr. Gianella is the executive director of the Last Gift Study, and she oversees all procedures related to recruitment, outreach, participant enrollment, and follow up. She is involved in the development of the rapid research autopsy procedures and the creation of lab-based techniques to process blood and tissues in an effort to characterize HIV reservoirs.

University of California – San Diego

Warner Greene, MD, PhD
co-Director Research Focus 1
Gladstone Institutes
San Francisco, CA

Dr. Greene will lead studies on the identification of novel silencing promoting genes and will investigate HIV persistence in the brain.

Joachim Hauber, PhD
Heinrich Pette Institute – Leibniz Institute for Experimental Virology
Hamburg, Germany

Dr. Hauber works on developing a scalable cure for HIV using next generation genome editing methods.

Heinrich Pette Institute – Leibniz Institute for Experimental Virology

Denise Hsu, Bsc(Med) MB BS, PhD
U.S. Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Bethesda, MD

Dr Hsu will supervise and coordinate the execution of NHP studies.

Military HIV Research Program

Esper Kallas, MD
University of Sao Paulo School of Medicine
Sao Paulo, Brazil

Dr. Kallas directs the clinical and community engagement efforts for the HOPE Collaboratory in Sao Paulo, Brazil.

University of Sao Paulo School of Medicine

Hannah Kibuuka, MBchB, MMed, MPH
Makerere University Walter Reed Project
Kampala, Uganda

Dr. Kibuuka brings tremendous clinical trials experience plus HIV cohort study leadership and as a co-investigator, she participates in all procedures related to recruitment, outreach, participant enrollment, and follow up.

Makerere University Walter Reed Project

Priti Kumar, PhD
Yale University School of Medicine
New Haven, CT

As part of HOPE, Dr. Kumar will direct a research program for targeting nucleic-acid editing/modifying molecules to HIV-infected cells for suppressing viral reactivation and excising provirus and direct studies in humanized mouse models of HIV infection and latency

Ulrike Lange, MD, PhD
Heinrich Pette Institute – Leibniz Institute of Experimental Virology and University Medical Center Hamburg-Eppendorf
Hamburg, Germany

Dr. Lange contributes her expertise on chronic HIV infection to provide cellular models of clinical relevance to test newly developed therapeutic strategies developed in HOPE.

Heinrich Pette Institute – Leibniz Institute of Experimental Virology and University Medical Center Hamburg-Eppendorf

Niren Murthy, PhD
The University of California at Berkeley and the Innovative Genomics Institute
Berkeley, CA

Dr. Murthy’s lab will be developing innovative ways for delivering genome editing enzymes to T cells.

The University of California at Berkeley and the Innovative Genomics Institute

Betty Mwesigwa, MBchB, MSc
Makerere University Walter Reed Project
Kampala, Uganda

Dr. Mwesigwa is the site principal investigator for the MUWRP study that collects biospecimens for the characterization of HIV reservoirs in different body compartments and oversees all procedures related to recruitment, community outreach, participant enrollment, and follow up for the HOPE study.

Makerere University Walter Reed Project

 
Avindra Nath, MD
National Institute of Neurological Disorders and Stroke
Bethesda, MD

Dr. Nath will work on understanding the role of HIV in the brain and the effects of ‘block-lock-excise’ strategies on HIV in the brain.

National Institute of Neurological Disorders and Stroke

Lishomwa Ndhlovu, MD, PhD
Weill Cornell Medicine
New York, NY

Dr. Ndhlovu research program is dedicated to confronting the challenges of HIV and aging using immuno-epigenetic approaches to resolve molecular mechanisms of HIV age related complications and viral persistence.

Doug Nixon, MD, PhD
Weill Cornell Medicine
New York, NY

Dr. Nixon's group will be working closely with Cedric Feschotte and his team to learn how HERVs may give clues to locking HIV.

Melanie Ott, MD, PhD
Gladstone Institute
San Francisco, CA

Dr. Ott is the Program Director for HOPE. Her work focuses on the role of reversible protein acetylation in HIV transcription and identifying molecular mechanisms controlling viral latency.

Nadia Roan, PhD
Gladstone Institutes
San Francisco, CA

Dr. Roan will investigate the mechanisms underlying transcriptional silencing of the HIV provirus, and the host features that prevent “block and lock” after a variety of therapeutic interventions.

Pauline Sameshima, PhD
Lakehead University
Thunder Bay, Ontario, Canada

Dr. Sameshima will work on developing cure curriculum and education through community arts integrated research.

Lakehead University

Susana Valente, PhD
Scripps Research
Jupiter, Florida

Dr. Valente’s research focuses on mechanisms that regulate HIV-1 latency in CD4+T memory T cells and development of antiviral molecules that suppress the latent reservoir.

Eric Verdin, MD
Buck Institute for Research on Aging
Novato, CA

Dr. Verdin works to understand the roles that metabolism and aging have on HIV and how they can be targeted to lock HIV in latent state.

The Buck Institute